BMS-303141
Based on 23 publication(s) in Google Scholar
BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.02%
- CAS No.: 943962-47-8
- Formule: C19H15Cl2NO4S
- Masse moléculaire:424.30
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) BMS-303141
More- Cell Metab. 2025 Oct 22:S1550-4131(25)00396-1. [Abstract]
- Gastroenterology. 2024 May;166(5):772-786.e14. [Abstract]
- Nat Cancer. 2023 Mar;4(3):344-364. [Abstract]
- Nat Commun. 2024 Jan 2;15(1):163. [Abstract]
- Mol Cell. 2022 Aug 18;82(16):3061-3076.e6. [Abstract]
- Cell Death Dis. 2025 Oct 7;16(1):715. [Abstract]
- Cell Chem Biol. 2024 Aug 15;31(8):1529-1541.e12. [Abstract]
- Free Radic Biol Med. 2024 Mar:213:443-456. [Abstract]
- J Agric Food Chem. 2021 Aug 11;69(31):8714-8725. [Abstract]
- J Bone Miner Res. 2021 Oct;36(10):2065-2080. [Abstract]
- Int J Mol Sci. 2022, 23(18), 10747.
- Int J Mol Sci. 2022 Sep 15;23(18):10747. [Abstract]
- J Pathol. 2020 Dec;252(4):358-370. [Abstract]
- Chem Biol Interact. 2022 Nov 1:367:110199. [Abstract]
- Neoplasia. 2026 Jul:77:101314. [Abstract]
- FASEB J. 2022 Jul;36(7):e22418. [Abstract]
- FEBS Lett. 2025 Oct;599(19):2817-2827. [Abstract]
- Fitoterapia. 2024 Jun:175:105956. [Abstract]
- Fitoterapia. 2024 Mar:173:105813. [Abstract]
- bioRxiv. 2026 Apr 20.
- SSRN. 2026 Mar 20.
- NAR Mol Med. 2026 Mar 24.
- bioRxiv. 2026 Feb 1.
Customer Validation & Images
-
2D/3D Cell Culture and Differentiation
-
Cell Proliferation/Viability Assay
-
WB
Activité biologique
IC50: 0.13 uM (ACL)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
8 μM
Compound: 9
|
Inhibition of total lipid synthesis HepG2 cells assessed as incorporation of [14C]total lipids after 6 hrs
Inhibition of total lipid synthesis HepG2 cells assessed as incorporation of [14C]total lipids after 6 hrs
|
[PMID: 17383874] |
In HepG2 cells, BMS-303141 shows inhibition of total lipid syntheses with an IC50 of 8 μM. BMS-303141 shows no cytotoxicity up to 50 lM under a cell based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 943962-47-8
-
Appearance Solid
-
Masse moléculaire 424.30
-
Formule C19H15Cl2NO4S
-
Color White to off-white
-
SMILES
O=S(C1=CC(Cl)=CC(Cl)=C1O)(NC2=CC(C3=CC=CC=C3)=CC=C2OC)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. [Abstract]2025 Oct 22:S1550-4131(25)00396-1. PMID: 41130202 -
Gastroenterology
2024 May;166(5):772-786.e14. PMID: 38272100 -
Nat Cancer
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling. [Abstract]2023 Mar;4(3):344-364. PMID: 36732635
BMS-303141 purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Mar;4(3):344-364. [Abstract]
3D spheroids growth upon genetic inhibition of either Cpt1a/CPT1A compared to cells infected with scramble as a control together with pharmacologic ALCY inhibition using BMS-303141 (20 μM, 5 days) in (d) 4T1 and (e) MCF10A H-RasV12 cells with or without extra palmitate and in the presence of the acetate as metabolic rescue (5 mM, 5 days).
-
Nat Commun
MCT1-governed pyruvate metabolism is essential for antibody class-switch recombination through H3K27 acetylation. [Abstract]2024 Jan 2;15(1):163. PMID: 38167945 -
Mol Cell
Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma. [Abstract]2022 Aug 18;82(16):3061-3076.e6. PMID: 35948010 -
Cell Death Dis
Fatty acid synthase-mediated lipid droplet formation enhances macrophage killing of Staphylococcus aureus. [Abstract]2025 Oct 7;16(1):715. PMID: 41057302 -
Cell Chem Biol
AspSnFR: A genetically encoded biosensor for real-time monitoring of aspartate in live cells. [Abstract]2024 Aug 15;31(8):1529-1541.e12. PMID: 38806058 -
Free Radic Biol Med
Sulforaphane impedes mitochondrial reprogramming and histone acetylation in polarizing M1 (LPS) macrophages. [Abstract]2024 Mar:213:443-456. PMID: 38301976 -
J Agric Food Chem
Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. [Abstract]2021 Aug 11;69(31):8714-8725. PMID: 34323067 -
J Bone Miner Res
Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation. [Abstract]2021 Oct;36(10):2065-2080. PMID: 34155695
BMS-303141 purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2021 Oct;36(10):2065-2080. [Abstract]
Various concentrations of BMS-303141-treated (0, 6.25, 12.5, 25 μM) BMMs for different time periods (1, 3, 5 days). The cell viability and proliferation were assessed by CCK8 tests.
BMS-303141 purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2021 Oct;36(10):2065-2080. [Abstract]
ANKL/M-CSF stimulated BMMs inthe presence of 25 μM BMS-303141 or control for indicated time periods (0, 1, 3, 5 days). Protein levels of indicated osteoclast markers were determined by Westernblot.
-
-
Int J Mol Sci
Discovery of Flavonoids as Novel Inhibitors of ATP Citrate Lyase: Structure-Activity Relationship and Inhibition Profiles. [Abstract]2022 Sep 15;23(18):10747. PMID: 36142671 -
J Pathol
ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p. [Abstract]2020 Dec;252(4):358-370. PMID: 32770671 -
Chem Biol Interact
Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay. [Abstract]2022 Nov 1:367:110199. PMID: 36174740 -
Neoplasia
Metabolic regulation of histone acetylation by ACLY supports MDR1 expression in colorectal cancer and highlights a targetable vulnerability. [Abstract]2026 Jul:77:101314. PMID: 42066427 -
FASEB J
LPS stimulation stabilizes HIF-1α by enhancing HIF-1α acetylation via the PARP1-SIRT1 and ACLY-Tip60 pathways in macrophages. [Abstract]2022 Jul;36(7):e22418. PMID: 35713568 -
FEBS Lett
2025 Oct;599(19):2817-2827. PMID: 40936396 -
Fitoterapia
Discovery and characterization of novel ATP citrate lyase inhibitors from Acanthopanax senticosus (Rupr. & Maxim.) Harms. [Abstract]2024 Jun:175:105956. PMID: 38604261 -
Fitoterapia
Formyl phloroglucinol meroterpenoids from the leaves of Eucalyptus globulus subsp. maidenii and their ATP-citrate lyase inhibitory activities. [Abstract]2024 Mar:173:105813. PMID: 38184174 -
-
-
-
Solvant et solubilité
DMSO : 25 mg/mL (58.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.89 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.89 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Mice: Effect of BMS-303141 in high-fat fed mice is studied. There are a total of four groups in the study; mice on normal diet and high-fat diet controls, and two treated groups that are supplemented with BMS-303141 in their high-fat diet to an equivalent daily dose of 10 or 100 mg/kg. The study is continued for a total of 34 days. Food consumption and body weight gain are tracked along with weekly assessment of lipid and glucose plasma chemistries[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3568 mL | 11.7841 mL | 23.5682 mL | 58.9206 mL |
| 5 mM | 0.4714 mL | 2.3568 mL | 4.7136 mL | 11.7841 mL | |
| 10 mM | 0.2357 mL | 1.1784 mL | 2.3568 mL | 5.8921 mL | |
| 15 mM | 0.1571 mL | 0.7856 mL | 1.5712 mL | 3.9280 mL | |
| 20 mM | 0.1178 mL | 0.5892 mL | 1.1784 mL | 2.9460 mL | |
| 25 mM | 0.0943 mL | 0.4714 mL | 0.9427 mL | 2.3568 mL | |
| 30 mM | 0.0786 mL | 0.3928 mL | 0.7856 mL | 1.9640 mL | |
| 40 mM | 0.0589 mL | 0.2946 mL | 0.5892 mL | 1.4730 mL | |
| 50 mM | 0.0471 mL | 0.2357 mL | 0.4714 mL | 1.1784 mL |
BMS-303141 Related Classifications
HY-16107 Related Classifications
Powered by Bioz